Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
RXRX Recursion Pharmaceuticals
- 6.130
- -0.460-6.98%
Close Mar 10 16:00 ET
- 6.160
- +0.030+0.49%
Pre 04:00 ET
2.46BMarket Cap-3.63P/E (TTM)
6.430High5.930Low24.03MVolume6.380Open6.590Pre Close146.89MTurnover6.28%Turnover RatioLossP/E (Static)401.99MShares12.36052wk High2.38P/B2.35BFloat Cap5.60052wk Low--Dividend TTM382.61MShs Float42.810Historical High--Div YieldTTM7.59%Amplitude4.540Historical Low6.113Avg Price1Lot Size
Recursion Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -24.81%-359.17M | -55.82%-115.43M | 18.78%-59.23M | -21.87%-82.22M | -39.53%-102.3M | -244.55%-287.78M | -65.54%-74.08M | -33.70%-72.92M | -9.48%-67.47M | -194.74%-73.32M |
| Net income from continuing operations | -41.33%-463.66M | -92.38%-178.91M | -3.04%-95.84M | -27.13%-97.54M | -39.87%-91.37M | -36.99%-328.07M | -61.75%-93M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M |
| Depreciation and amortization | 49.55%36.49M | 71.47%12.95M | -5.01%7.2M | 61.79%8.97M | 97.88%7.38M | 107.57%24.4M | 135.00%7.55M | 153.53%7.58M | 98.96%5.54M | 34.73%3.73M |
| Other non cash items | 111.34%24.2M | 109.05%13.69M | 4,900.00%8.5M | -95.41%93K | -29.29%1.91M | 33.76%11.45M | 168.88%6.55M | -90.41%170K | -8.20%2.03M | 26.12%2.7M |
| Change In working capital | 24.39%-38M | 153.66%6.05M | 159.75%2.67M | -1.41%-10.26M | -49.36%-36.45M | -147.90%-50.26M | -1,775.21%-11.27M | 42.54%-4.46M | -6.12%-10.12M | -119.87%-24.4M |
| -Change in receivables | 21.73%-6.07M | 24.82%-4.83M | -362.56%-939K | 190.42%736K | -228.08%-1.04M | -387,700.00%-7.76M | -215.25%-6.42M | -105.37%-203K | 54.78%-814K | 95.80%-317K |
| -Change in payables and accrued expense | 38.56%11.69M | 339.35%21M | -47.78%4.39M | -10.45%4.26M | -88.89%-17.96M | 392.53%8.44M | -50.65%4.78M | 131.91%8.41M | 207.30%4.76M | 27.67%-9.51M |
| -Change in other current liabilities | -58.00%-15.58M | -133.32%-4.46M | -87.52%-4.7M | 12.47%-2.62M | -55.24%-3.79M | -38.71%-9.86M | 12.41%-1.91M | -18.58%-2.51M | -93.79%-3M | -93.20%-2.44M |
| -Change in other working capital | 31.74%-28.04M | 26.59%-5.66M | 138.55%3.92M | -14.19%-12.64M | -12.54%-13.66M | -137.23%-41.08M | 43.58%-7.72M | 22.16%-10.16M | -43.01%-11.07M | -108.38%-12.13M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -24.81%-359.17M | -55.82%-115.43M | 18.78%-59.23M | -21.87%-82.22M | -39.53%-102.3M | -244.55%-287.78M | -65.54%-74.08M | -33.70%-72.92M | -9.48%-67.47M | -194.74%-73.32M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 2,642.62%260.06M | 11,171.38%275.46M | -1,214.70%-4.56M | -103.70%-4.18M | -24.59%-6.65M | -105.29%-10.23M | 68.82%-2.49M | -100.65%-347K | -141.56%-2.05M | -103.73%-5.34M |
| Net PPE purchase and sale | -14.55%-13.7M | 37.20%-1.3M | -512.35%-4.56M | 70.21%-1.18M | -28.56%-6.65M | 67.74%-11.96M | 74.09%-2.07M | 90.98%-745K | 75.92%-3.97M | -19.18%-5.18M |
| Net intangibles purchase and sale | -461.14%-3.35M | 0.00%-350K | --0 | ---3M | --0 | -99.00%-597K | ---350K | 72.67%-82K | --0 | ---165K |
| Net business purchase and sale | 14,927.33%277.1M | 390,387.32%277.1M | --0 | ---- | ---- | --1.84M | ---71K | --0 | ---- | ---- |
| Net investment purchase and sale | --0 | --0 | ---- | ---- | ---- | -99.79%480K | --0 | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 2,642.62%260.06M | 11,171.38%275.46M | -1,214.70%-4.56M | -103.70%-4.18M | -24.59%-6.65M | -105.29%-10.23M | 68.82%-2.49M | -100.65%-347K | -141.56%-2.05M | -103.73%-5.34M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 117.02%304.12M | -86.81%10.64M | -69.38%16.46M | 6,848.03%263.12M | 623.05%13.9M | -9.21%140.13M | -45.23%80.66M | 2,200.60%53.77M | 41.94%3.79M | -7.77%1.92M |
| Net issuance payments of debt | -479.63%-4.44M | -202.74%-2.1M | -9,429.17%-2.29M | -8.33%-26K | -8.33%-26K | -751.11%-766K | -2,917.39%-694K | -4.35%-24K | -9.09%-24K | -9.09%-24K |
| Net common stock issuance | 134.53%300.42M | -85.88%11.03M | -66.06%16.97M | --261.55M | --10.87M | -10.87%128.09M | -45.66%78.09M | --50M | --0 | --0 |
| Proceeds from stock option exercised by employees | -36.41%8.14M | -47.55%1.71M | -53.00%1.78M | -57.96%1.6M | 56.73%3.05M | 19.41%12.81M | -8.63%3.26M | 60.55%3.79M | 41.67%3.81M | -7.60%1.95M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 117.02%304.12M | -86.81%10.64M | -69.38%16.46M | 6,848.03%263.12M | 623.05%13.9M | -9.21%140.13M | -45.23%80.66M | 2,200.60%53.77M | 41.94%3.79M | -7.77%1.92M |
| Net cash flow | ||||||||||
| Beginning cash position | -28.20%401.43M | 9.72%435.83M | 15.82%482.75M | -36.53%306.15M | -28.20%401.43M | 89.31%559.11M | -14.56%397.21M | -10.19%416.82M | -6.90%482.38M | 89.31%559.11M |
| Current changes in cash | 229.85%205.01M | 4,068.66%170.67M | -142.67%-47.33M | 368.85%176.72M | -23.88%-95.06M | -159.79%-157.88M | -95.67%4.09M | -2,600.26%-19.5M | -21.69%-65.73M | -134.44%-76.73M |
| Effect of exchange rate changes | -1,911.70%-3.41M | -2,900.00%-3.47M | 450.43%403K | -165.19%-118K | -10,850.00%-219K | 161.24%188K | 140.39%124K | ---115K | --181K | ---2K |
| End cash Position | 50.22%603.02M | 50.22%603.02M | 9.72%435.83M | 15.82%482.75M | -36.53%306.15M | -28.20%401.43M | -28.20%401.43M | -14.56%397.21M | -10.19%416.82M | -6.90%482.38M |
| Free cash flow | -25.27%-376.22M | -53.06%-117.08M | 13.51%-63.79M | -20.95%-86.4M | -38.52%-108.95M | -148.45%-300.33M | -45.08%-76.49M | -16.87%-73.75M | 8.53%-71.44M | -207.68%-78.66M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |